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Abstract
Oral anticoagulation (OAC) is highly effective for stroke prevention in high-risk-patients with 
atrial fibrillation (AF). AF is also a risk for dementia, and effective OAC reduces the risk of  
dementia. Up to 30% of patients with AF have a coronary artery disease and antiplatelets are 
used to avoid thrombotic complications. Patients with AF often have an acute coronary syndrome  
(ACS) and undergo a percutaneous intervention with stent-implantation. These patients re-
quire a triple therapy, i.e. the combination of OAC with dual-antiplatelet therapy. It is obvious 
that OAC may induce bleeding with potentially deleterious effects on mortality. Even the occur-
rence of minor bleeding is problematic.
The review describes available data on used anti-thromboembolic regimens in patients treated 
with OAC (vitamin K antagonists and non-vitamin K antagonists) who need a triple therapy 
(i.e. anticoagulation and antiplatelets). Most data are from patients who were treated for an 
ACS and cannot be directly extrapolated for patients with AF. The impact of used stents and 
novel P2Y12 antagonist-antiplatelets and duration of triple therapy is discussed. Often some 
high-risk patients with AF would need anticoagulation but cannot be given this therapy be-
cause of excessive bleeding risks or contraindicating comorbidities: in these patients left atrial 
appendage closure with an occluding device can be used as an alternative to anti-thromboem-
bolic therapy.
The unavoidable anti-thromboembolic triple therapy carries a strong potential for bleeding 
events, which increase mortality. We have many data and several recommendations are offered. 
Nonetheless, we lack solid data on the best anti-thromboembolic regimen in patients with AF 
who need anticoagulation and antiplatelets. (Cardiol J 2016; 23, 2: 211–223)
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Introduction
In high-risk-patients with atrial fibrillation 
(AF), oral anticoagulation (OAC) is highly effective 
in reducing stroke by 64%, all-cause mortality by 
26% [1–4] and the risk for dementia [5, 6]. In coro-
nary artery disease (CAD), antiplatelets are ef-
fective for reducing thrombotic complications [7]. 
Almost a third of AF-patients have a CAD, many 
develop an acute coronary syndrome (ACS) 
and undergo a percutaneous coronary interven-
tion with stent implantation (PCI-SI). After PCI-
-SI anticoagulated AF-patients require a triple 
therapy (TT), i.e. OAC with dual-antiplatelet 
therapy (DAPT). Indeed, almost 10% of patients 
undergoing PCI-SI are on OAC [8]. We review the 
anti-thromboembolic regimens (ATRs) in these 
patients.
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Methodology of our search  
in the literature
A review must rely on solid data and be objec-
tive, delivering the “state of the art” of the chosen 
argument. We believe that the reviewers should 
personalize the data.
We started a goal-oriented search in English 
with the search engines BioMedSearch.com, 
Cardiosource, CenterWatch, ClinicalTrials.gov, 
Cochrane Summaries, Google Scholar, MedWatch 
and PubMed. We settled a time-window 2005 till 
2015 with key words AF and ACS, stent implanta-
tion and ATRs, TT, and OAC. This search deliv-
ered more than 1 million references. By necessity, 
we restricted our search to a time window 2010 
till 2015 and ‘filters’ for guidelines and meta-
analyses. This search delivered more than 90,000 
references. We used plagiarism checker software 
and found that many papers were from the same 
authors, even if the authors order was changed 
or some authors were changed. One might mali-
ciously say that some papers were repeating data 
in different journals. We selected the most recent 
papers with large numbers of cases and ended 
with a total of 400 references. From the abstracts 
we selected 150 full-text papers. Eighty papers 
gave the “state of the art” about our review. It 
is unavoidable that we may have selected same 
papers by chance.
Risks of oral anticoagulation
Obviously, OAC may induce bleeding with po-
tentially deleterious effects on mortality [3, 8, 9]. 
In major bleeding, anemia and hypovolemic shock 
contribute to mortality mechanically and also by 
triggering inflammatory responses and ischemic 
events [1–3]. Even the occurrence of minor bleed-
ing is problematic. Indeed, nuisance bleeding was 
associated with cessation of clopidogrel-therapy in 
more than 10% of patients, which in turn resulted in 
an increased rate of thrombotic complications [10].
For decades vitamin K antagonists (VKAs), 
e.g. acenocoumarol, phenprocoumon and warfarin, 
were used for OAC [1–3, 6, 7]. In recent years 
direct novel oral anticoagulants (NOACs) have 
been marketed (at present apixaban, dabigatran, 
edoxaban and rivaroxaban) and have a positive 
risk/benefit ratio over VKAs [1–3, 7, 11–14]. The 
number of patients who are first treated with, 
or are switched from VKAs to NOACs, is stead-
ily increasing [1–3, 15–18]. Nonetheless, cost of 
NOACs is high and their use is more problematic 
than expected [15]. Major bleeding (especially in-
tracerebral hemorrhage) occurs significantly less 
frequently with NOACs [1–3, 15–18], but gastro-
intestinal and nasal bleedings are not rare. Dabi-
gatran causes dyspepsia in about 10% of patients 
[1–3, 15–17]. NOACs have short half-lives and if 
patients miss 2 doses they will be unprotected. 
A recent review has shown that morbid adiposity 
may reduce the efficacy of NOACs [19]. NOACs 
have fewer pharmacokinetic/-dynamic interactions 
than VKAs but they have important interactions 
with inhibitors of the P-glycoprotein transporter 
and with several drugs used in cardiology [15–17, 
20–22]. Table 1 shows potentially toxic pharmaco-
logic interactions of NOACs.
Might NOACs be better than VKAs  
in triple therapy?
It might be hypothesized that replacing in TT 
VKAs by NOACs would improve the risk/benefit 
ratio. In common clinical practice it is not rare to 
see patients who are off-label treated with NOACs 
in combination with aspirin and either prasugrel 
Table 1. Pharmacologic interactions of novel oral anticoagulants (NOACs) with frequently used drugs.
Dangerous interactions of NOACs with:
Cyclosporine Especially dabigatran
Dronedarone All NOACs
Ketoconazole, itraconazole, voriconazole Apixaban, dabigatran, rivaroxaban
HIV-protease inhibitors Especially apixaban, dabigatran and rivaroxaban
Quinidine Apixaban, dabigatran, rivaroxaban
Possibly dangerous interactions with:
Amiodarone Apixaban, dabigatran, edoxaban
Verapamil Dabigatran
Minor interactions with:
H2-blockers All NOACs
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or ticagrelor (a therapy which is contraindicated 
in modern guidelines). This use has also been 
documented in the XANTUS study [18], which has 
proven that rivaroxaban is also used in patients 
with severe renal insufficiency (a contraindication), 
in dosages which are not recommended from the 
company or in guidelines, and in combination with 
modern antiplatelets (a contraindicated therapy).
The direct factor Xa-antagonist, apixaban [23], 
and the direct thrombin-inhibitor, dabigatran [24] 
were used to prevent stent-thrombosis after PCI-SI, 
at doses proven be effective in non-valvular AF, 
in ACS-patient and in combination with aspirin and 
clopidogrel. Apixaban and dabigatran cannot be 
combined at the used doses with DAPT because 
dabigatran was associated with a higher risk of ACS 
and both apixaban and dabigatran induced excessive 
bleeding and had no antiischemic benefit [25, 26]. 
However, the real world XANTUS study has shown 
that the direct factor Xa-antagonist rivaroxaban 
induces less bleeding, especially intracerebral 
hemorrhage, than VKAs [18]. Indeed rivaroxaban 
underwent a dose-finding trial in ACS-patients who 
were treated with antiplatelets and it was proven 
that this TT with very low doses of rivaroxaban 
(2.5 mg bid) and DAPT provided the best effect/risk 
profile in the thromboembolic prophylaxis [27, 28]. 
These results were extended and confirmed in the 
ATLAS ACS 2-TIMI 51 trial [29]: in ACS-patients 
rivaroxaban (2.5-mg bid) and DAPT (aspirin + 
+ clopidogrel) lead to a highly significant 1.8% 
reduction (p < 0.0001) in all-cause mortality, fur-
thermore, rivaroxaban demonstrated an additional 
protective effect against stent-thrombosis. Because of 
these encouraging results, the PIONEER trial [30] 
is testing whether these results can be transferred 
to AF-patients when TT is needed. At present, the 
use of NOACs in the TT in AF remains a possible 
therapy requiring further investigations.
Anti-thromboembolic regimens in AF
Historical trials have shown that VKAs are 
partially effective in preventing thromboembolic 
events after a myocardial infarction (MI) [29]. 
However, monotherapy with VKAs is therapeuti-
cally insufficient in CAD and it is no longer rec-
ommended by modern guidelines in patients who 
undergo PCI-SI [9, 31–36]. On the other hand, 
DAPT without OAC is less effective than VKAs in 
reducing thromboembolic complications [9]. TT 
(VKAs, aspirin + clopidogrel) was found to reduce 
stent-thrombosis rates to 1% in the first month and 
to 1–2% in the first year [9]. Therefore, modern 
guidelines recommend DAPT (aspirin + a P2Y12-
-antagonist) as the most effective strategy to prevent 
thrombosis in anticoagulated patients who undergo 
PCI-SI. Even if considered dangerous, it is not 
rare to see patients who are off-label treated with 
OAC (either VKAs or NOAC) in combination with 
prasugrel or ticagrelor.
Several studies analyzed the effect of different 
ATRs in anticoagulated patients. Most studies were 
retrospective, having the advantage of a shorter 
duration and allowing large number of cases over 
a long-time. They are not head to head studies and 
lack real comparative data.
• A study analyzed data from 478 patients who 
underwent PCI-SI [37]. Several ATRs were com-
pared: 1) TT, i.e. warfarin + DAPT (aspirin + clopi-
dogrel, 100 + 75 mg/day), 2) warfarin + aspirin 
100 mg/day, 3) warfarin + clopidogrel 75 mg/day, and 
4) DAPT (aspirin + clopidogrel) alone. Most results 
are shown in Table 2. No differences were observed 
in major bleeding in warfarin + aspirin vs. warfarin + 
+ DAPT (6.1% vs. 6.6%), but patients treated with 
warfarin + aspirin had a significantly (p < 0.01) 
higher risk for stent-thrombosis (15.2% vs. 1.9%) 
or MI (18.2% vs 8.5%), than those on warfarin + 
+ DAPT. Of note, in patients treated with warfarin + 
+ clopidogrel there was no significant difference 
in the occurrence of stent-thrombosis (0.0% vs. 
1.9%) or MI (11.1% vs. 8.5%) as compared with 
patients treated with other ATRs. At 12-month 
follow-up patients treated with DAPT alone had 
a significantly higher rate of stroke (8.8% vs. 2.8%) 
or stent-thrombosis (5.9% vs. 1.9%, p < 0.01) than 
those on warfarin + DAPT. In this study the number 
of patients is insufficient to detect rare events.
• A single-center prospective study analyzed data 
from 426 AF-patients who underwent PCI-SI [38]. 
TT, i.e. VKAs + DAPT (aspirin 100 mg/day + 
+ clopidogrel 75 mg/day) was compared with DAPT 
alone. TT was used in 50% of patients and DAPT 
alone in 41%. Relevant results are shown in Table 3. 
Mortality rates were significantly higher (28% 
vs. 18%, p < 0.01) in patients treated with DAPT 
alone. Of note, also in this prospective study the 
number of patients is insufficient to detect rare events.
• The ACTIVE W study analyzed data from low-
risk, non-anticoagulated AF-patients with ACS who 
underwent PCI-SI [39, 40]. Several ATRs were 
used: 1) TT, i.e. VKAs + DAPT (aspirin + clopi-
dogrel), 2) VKAs + single antiplatelet, or 3) VKAs + 
+ placebo. The median follow-up was 3.6 years. Rel-
evant results are shown in Table 2. Patients treated 
with VKAs + antiplatelets had significantly (p < 0.01) 
more major cardiovascular events (MACE) 
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Table 2. Triple therapy versus vitamin K antagonist + aspirin, versus vitamin K antagonist + clopi-
dogrel, versus dual-anti-platelet therapy.
Author/ 
/References
Design No. of 
patients
Mean  
follow-up
Endpoints
Karjalainen  
et al. [37]
Retrospective, 
6 studies
479 12 months Warfarin vs. aspirin and TT similar major bleeding 
(6.1, 6.6%)
Warfarin + aspirin more stent thrombosis vs. TT 
(15.2, 1.9%)
Warfarin + aspirin vs. TT more MI (18.2, 8.5%)
Warfarin + clopidogrel vs. TT similar stent  
thrombosis (0.0, 1.9%) and MI (11.1, 8.5%)
DAPT vs. TT more stent thrombosis (8.8, 2.8%)
Sambola  
et al. [38]
Prospective,  
3 centers
405 6 months DAPT vs. other ATRs more mortality (28, 18%)
TT vs. other ATRs more major bleeding (6.5, 4.3%) 
and minor bleeding (11.2, 6.5%)
TT vs. other ATRs less CVE (7.9, 15.2%)  
and less stent thrombosis (4.0, 8.7%)
ACTIVE W 
[39, 40]
Prospective, 
12 centers
? 3.6 years VKA + antiplatelets vs. VKA placebo more MACE
VKA + clopidogrel vs. VKA + placebo less MI but 
more major bleeding
ATR — anti-thromboembolic regimens; CVE — cardiovascular events; DAPT — dual-anti-platelet therapy (aspirin + clopidogrel); MI — myo-
cardial infarction; TT — triple therapy (VKAs + DAPT); VKA — vitamin K antagonist
(6.8% per year) than those receiving VKAs + 
+ placebo. MI occurred significantly (p = 0.08) 
less often with VKAs + clopidogrel (115 patients) 
than with VKAs + placebo (90 patients) but ma-
jor bleeding occurred significantly (p < 0.001) 
more often with VKAs + clopidogrel (251 pa-
tients, 2.0% per year) than with VKAs + placebo 
(162 patients, 1.3% per year). Thus, in low-risk 
AF-patients who underwent PCI-SI, an ATRs 
with VKAs + antiplatelets reduced the risk of 
major vascular events, especially stroke, whereas 
it increased the risk of major hemorrhage. The 
message is that in low-risk, non-anticoagulated 
AF-patients who undergo PCI-SI, ATRs with TT 
and also VKAs + single antiplatelet show a poor 
efficacy/risk profile.
• A retrospective single-center study [41] ana-
lyzed data from 405 anticoagulated patients who 
underwent PCI-SI. Several ATRs were studied: 
1) TT, i.e. VKAs + DAPT (aspirin + clopidogrel, 
100 and 75 mg/day); 2) VKAs + single antiplate-
let, and 3) DAPT alone. TT was used in 50% of 
patients and DAPT alone in 41%. Relevant results 
are shown in Table 3. TT was more effective than 
VKAs + aspirin, but VKAs + clopidogrel had 
a similar efficacy. Bleeding rates were not signifi-
cantly different between TT and VKAs + single 
antiplatelet (respectively, 15.5% and 13.0%); how-
ever, MACE occurred more frequently in patients 
treated with VKAs + single-antiplatelet (15.2%) 
as compared with those treated with TT (7.9%) 
or DAPT (1.2%). Of note, the number of patients is 
Table 3. Triple therapy versus dual-anti-platelet therapy.
Author/ 
/References
Design No. of  
patients
Mean  
follow-up
Endpoints
Ruiz-Nodar  
et al. [41]
Retrospective,  
1 center
479 594 days DAPT vs. TT higher mortality (28, 18%)
TT vs. ATR higher major bleeding (14.9, 9%)  
and minor bleeding (12.6, 9%)
Ruiz-Nodar  
et al. [42]
Retrospective,  
2 centers
604 693 days DAPT vs. TT more MACE (38.7, 2.65%)
ATR — antithrombotic regiments; DAPT — dual-anti-platelet therapy (aspirin + clopidogrel); MACE — major cardiovascular events;  
MI — myocardial infarction; TT — triple therapy (VKA + DAPT); VKA — vitamin K antagonist
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small and some data are puzzling. It is difficult to 
understand why major bleeding rates were slightly 
higher for DAPT than for TT and the reported 
stent-thrombosis rate of 15% is much higher than 
in most recent trials on PCI-SI. Mortality rates 
were significantly higher (28% vs. 18%, p < 0.01) 
in patients treated with DAPT alone. Of note, also 
in this study the number of patients is insufficient 
to detect rare events.
• A retrospective 2-center study from the same 
authors [42] analyzed data from 604 AF-patients 
who underwent PCI-SI. Patients were matched 
using propensity scores. TT, i.e. VKAs + DAPT 
(aspirin + clopidogrel, 100 and 75 mg/day) was 
compared with DAPT alone. Relevant results are 
shown in Table 3. Bleeding was significantly more 
frequent with TT than with DAPT. Of note in this 
study the number of patients was small, the odds 
ratio, hazard ratio and confidence interval were not 
reported.
Meta-analyses and registries
• A meta-analysis of 9 trials [43] assessed the 
results from 5,181 anticoagulated AF-patients 
who underwent PCI-SI. TT, i.e. warfarin + DAPT 
(aspirin + clopidogrel, 100 and 75 mg/day) was 
compared with DAPT alone. Relevant results are 
shown in Table 4. The overall incidence of death 
(p = 0.56) and MI (p = 0.38) was comparable. Howev - 
er, TT was significantly (p = 0.0004) more effective 
than DAPT in reducing ischemic stroke, but with 
a significantly (p < 0.0001) 2-fold increased risk of 
major bleeding. These results are along those from 
the other trials; TT is significantly more effective than 
DAPT alone, but carries a significant bleeding risk.
• A registry [44] assessed the occurrence of MACE 
in 118,606 anticoagulated AF-patients who under-
went PCI-SI and were treated with either VKAs 
alone or TT (VKAs + DAPT). Relevant results are 
shown in Table 4. The overall incidences of death 
or MI were comparable with all ATRs. However, 
TT was significantly (p < 0.0004) more effective 
in stroke prevention than DAPT alone but carried 
a significantly (p < 0.0001), 2-fold increased risk 
of major bleeding. During a mean follow-up of 3.3 
years the risk of bleeding was more than 3-fold 
elevated compared with VKAs monotherapy. Of 
note, in this registry, patients were not randomized 
and it is difficult to detect possible differences among 
the various ATRs.
• A Danish nationwide registry [45] collected 
data from 11,480 AF-patients with either acute 
MI (76.4%) or after elective PCI-SI (23.6%). 
A group of 17.3% of all patients with MI under-
went PCI-SI within 1 week, but only 13% were 
treated with TT. Results are shown in Table 4. 
The registry indicates that, although OAC was 
indicated, not all patients at increased bleed-
ing risk were treated with VKAs + DAPT. Data 
from this registry show a common therapeutic 
problem emerging when TT should be used: the 
fear of the bleeding risks related to TT seems to 
prevent physicians from referring anticoagulated 
ACS-patients for a PCI-SI. Thus, in this registry, 
bleeding in patients treated with TT patients may 
be underestimated.
• A multinational registry [46] collected data from 
9 clinical trials in 1,996 anticoagulated (with VKAs) 
patients who underwent PCI-SI. Few drug-eluting 
stents (DES) were used. Patients were discharged 
either on TT, i.e. VKAs + DAPT (aspirin + clopi-
dogrel, 100 mg + 75 mg/day) or VKAs + single 
antiplatelet. The ischemic events at a 6-month 
follow-up were compared. Relevant results are 
shown in Table 4. Stent-thrombosis rates did not 
increase excessively when patients were treated 
with VKAs + single antiplatelet. However, TT was 
significantly (p < 0.005) more effective to prevent 
MACE and even with regard to mortality (p < 0.01), 
but was accompanied by significantly (p < 0.04) more 
major bleeding events. These data support those 
from other studies.
• The CRUSADE registry [47] collected data 
from 5,673 anticoagulated (with warfarin) AF- 
-patients with a non-ST-elevation-ACS. A group 
of 1,247 (22%) patients underwent PCI-SI and 
were discharged on three different ATRs: 60% on 
TT, i.e. warfarin + DAPT, 31% on DAPT (aspirin + 
+ clopidogrel, 100 and 75 mg/day), and 3% on 
warfarin + aspirin. Results are shown in Table 4. 
Warfarin + aspirin was at least as effective as TT 
(warfarin + DAPT) to prevent coronary ischemic 
events but was associated with less bleeding 
complications.
Similar data were reported in the GRACE trial 
[48, 49]. Eight hundred patients with PCI-SI for 
ACS were analyzed. One hundred and thirty pa-
tients received DES. Patients were discharged on 
warfarin and either DAPT (580 patients, aspirin + 
+ either clopidogrel or ticlopidine) or single anti-
platelet therapy (220 patients). Data are shown in 
Table 4. The use of warfarin + single antiplatelet 
therapy was more common in Europe than in the 
United States (34% vs. 17%, p < 0.001). There was 
no difference in major bleeding in hospital or in 
6-month mortality or MI. In the single antiplatelet 
group, the use of either aspirin or thienopyridine 
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Table 4. Meta-analyses and registries (TT, VKA and DAPT).
Author/References Design No. of  
patients
Endpoints
Gao et al. [43] Meta-analysis, 
9 trials
5,181 TT vs. DAPT similar death and MI
TT vs. DAPT less strokes but 2-fold more major bleeding
Hensen et al. [44] Registry 118,606 TT and VKA + SA and DAPT similar death and MI
TT vs. DAPT better stroke prevention but 2-fold more  
major bleeding
Lamberts et al. [45] Registry 11,480 After PCI-SI only 13% of atrial fibrillation-patients  
received TT
Zhao et al. [46] Registry,  
9 trials
1,196 VKA + SA vs. TT similar stent thrombosis
TT vs. VKA + SA less MACE and less mortality but  
more major bleeding
CRUSADE [47] Registry 5,673 TT and VKA + aspirin same reduction in coronary  
ischemic events
TT vs. VKA + SA more major bleeding
GRACE [48, 49] Registry 800 Warfarin + clopidogrel or ticlopidine has similar mortality 
and MI
DAPT — dual-anti-platelet therapy (aspirin + clopidogrel); MACE — major cardiovascular events; MI — myocardial infarction; PCI-SI — per-
cutaneous coronary intervention with stent implantation; TT — triple therapy (VKA + DAPT); VKA — vitamin K antagonist; SA — single anti-
platelet
(clopidogrel or ticlopidine) in combination with 
warfarin resulted in similar outcomes.
Data from the last two registries differ from 
other studies and support the knowledge that stent-
thrombosis rates do not increase excessively when 
patients are treated VKAs + single antiplatelet in 
comparison to TT. Of note, in these registries, the 
number of patients who received a DES is insufficient 
to draw final conclusions.
Finally, in the LAST trial [50] with the stents 
used till 2005, the ATR with VKAs + aspirin was 
less effective than TT to prevent stent thrombosis.
Comparing the above trials is problematic. 
Most studies were retrospective and observational, 
the number of patients is too low to draw conclusive 
information, selected patients were different and the 
definition of bleeding was not the same. In 2014, the 
Bleeding Academic Research Consortium offered 
a new definition but we are still looking for an ac-
ceptable definition of major bleeding [51]. However, 
it can be considered proven that anticoagulated 
AF-patients who undergo PCI-SI have significantly 
more MACE when they are not discharged on TT, 
but that TT clearly carries an increased risk for 
bleeding. Thus, in AF-patients who need TT we 
are still looking for an ATRs with good protection 
from thromboembolic events without high bleed-
ing risks.
Duration of triple therapy
• The randomized, open-label trial ISAR-TRIPLE 
trial [52, 53] was performed in 3 European centers 
and involved 614 patients. Anticoagulated patients 
who underwent PCI-SI (with DES) received 
a TT, i.e. VKAs + DAPT (aspirin + clopidogrel). 
The primary endpoint was a composite of death, 
MI, definite stent-thrombosis, stroke, or major 
bleeding. The effects of a 6-week vs. 6-month 
TT-duration were compared. Results are shown 
in Table 5. The primary endpoint occurred in 
30 (9.8%) patients in the 6-week arm compared with 
27 (8.8%) patients 6-month arm (p = 0.63). There 
were no significant differences for the secondary 
combined ischemic endpoint of cardiac death, MI, 
definite stent-thrombosis and ischemic stroke 
(p = 0.87), or the secondary bleeding endpoint of 
thrombolysis in myocardial infarction (TIMI) major 
bleeding (p = 0.44). Thus net clinical outcomes were 
similar with a 6-week and a 6-month TT. These 
results suggest that physicians should weigh the 
trade-off between ischemic and bleeding risk when 
choosing the shorter or longer duration of TT.
• The prospective, multicenter, open-label, rand-
omized WOEST trial [54] was performed in 15 Bel-
gian and Dutch hospitals. A group of 573 patients 
who were anticoagulated with VKAs for at least 
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Table 5. Duration of triple therapy (TT).
Author/References Design No. of 
patients
Endpoints
ISAR-TRIPLE [52, 53] Randomized, 
open-label
614 6-week vs. 6-month TT: death was similar (9.8% vs. 
8.8%), also similar, MI, stent thrombosis, ischemic 
stroke and TIMI major bleeding
WOEST [54] Randomized, 
multicenter, 
open-label
573 VKA + single antiplatelet vs. TT: significantly less minor 
bleeding and major bleeding (19.5 vs. 44.9%), also less 
frequent MI, stroke, stent thrombosis and intracranial 
bleeding
MI — myocardial infarction; TIMI — thrombolysis in myocardial infarction; VKA — vitamin K antagonist
1 year and were scheduled for PCI-SI were rand-
omized to different ATRs: 1) TT, i.e. VKAs + DAPT 
(aspirin + clopidogrel, 80 and 75 mg/day), 2) VKAs + 
+ aspirin 80 mg/day, and 3) VKAs + clopidogrel 
75 mg/day. The ATRs was continued for 1 month 
after bare-metal stent (BMS) implantation (35% 
of patients), or for 1 year after DES-implantation 
(65% of patients). Follow-up time was 1 year. The 
primary endpoint of all types of TIMI minimal, 
minor and major bleeding was significantly (p < 
< 0.001) reduced in the VKAs + single antiplatelet 
vs. TT (19.5% vs. 44.9%). Minimal bleedings were 
also significantly reduced, while major bleeding 
events were numerically lower but did not reach 
statistical significance. Intracranial bleeding was 
unchanged. Although the trial was not powered 
for the analysis of ischemic events, it is interesting 
to note that MI, stroke, and stent-thrombosis were 
numerically lower and mortality was significantly 
lower in VKAs + single antiplatelet.
Concluding, we have many data but at present 
the best duration and type of ATRs in AF-patients 
who undergo PCI-SI is unknown. The available 
information can be considered hypothesis-gen-
erating.
Third-generation P2Y12 antagonists
In AF-patients who undergo PCI-SI, the oc-
currence of stent-thrombosis is substantially in-
creased if TT is not used and most published data 
have shown that monotherapy with DAPT (aspirin 
+ clopidogrel) has tested inferior compared with 
VKAs to reduce thromboembolic events [1–3, 9, 
15, 54–59]. In ACS-patients who undergo PCI-SI, 
anti-thromboembolic monotherapy with VKAs is 
not an alternative to DAPT therapy. Thus, the 
current standard of secondary prevention of athero-
thrombotic events in these patients includes a TT, 
i.e. OAC in combination with DAPT with aspirin 
and a P2Y12 receptor-antagonist. Compared with 
clopidogrel and ticlopidine, the third-generation 
P2Y12 receptor-antagonists (at present cangrelor, 
prasugrel and ticagrelor) provide faster, stronger, 
and more reliable antiplatelet activity [31–36].
The 2015 updated European Society of Car-
diology (ESC) guidelines [36] recommend that 
ACS-patients should be divided into four groups: 
very-high-risk, high-risk, middle-risk and low- 
-risk. This stratification should be used to choose 
a specific type of interventional and medical. 
In the 2015 ESC guidelines [36], prasugrel and 
ticagrelor have class I recommendations for the 
treatment of ACS and there is a class II indication 
for the recently approved cangrelor. Based on the 
TRITON-TIMI 38 [60, 61] and PLATO [62] trials, 
the guidelines recommend a 12-month DAPT with 
new DES. In selected cases the duration of DAPT 
could be longer than 12 months, for clopidogrel or 
prasugrel up to 30 months [60–64], for ticagrelor 
up to 48 months [61, 62, 65]. However, because of 
observed bleeding complications it is recommend 
not using prasugrel prior to PCI-SI [60–64]. The 
PEGASUS-TIMI 54 trial [cited in 36] suggests 
that the superior anti-thromboembolic efficacy of 
DAPT with aspirin + ticagrelor comes at cost of 
increased bleeding events. In the observational 
TRITON-TIMI 38 trial [60, 61], prasugrel was 
compared with clopidogrel in DAPT: minor and 
major bleeding occurred significantly (p < 0.03) 
more often with prasugrel than with clopidogrel 
and no significant difference in ischemic endpoints 
was observed. Thus, we know that ticagrelor and 
prasugrel are more effective in ACS but cause 
more bleeding than clopidogrel. Another aspect of 
P2Y12 receptor-antagonists is unrelated to bleeding 
risks. The TRILOGY trial [65] reported higher 
rates of cancer-related death among patients re-
ceiving either 60 mg/day or 90 mg/day ticagrelor 
than among those receiving placebo (1.10% and 
0.92% vs. 0.76%). A Food and Drug Association 
(FDA)-review reported the association between 
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bleeding and solid cancers with prasugrel [66] and 
another FDA review on DAPT [67] documented 
that the relative risk of the incidence of solid tumors 
was about 1.2% with clopidogrel and 1.3% with 
prasugrel, as compared with placebo. However, the 
FDA reviewed the data concluding that causality of 
cancer was unlikely and the chance of a false posi-
tive finding was high [68]. This conclusion was also 
supported by the prospective assessment of cancer 
in the TRILOGY trial [65], which showed no excess 
of cancers with ticagrelor 90 mg of ticagrelor as in 
in the PLATO trial with clopidogrel [62].
Of note, the ESC recommendations are only 
valid for non-ST-elevation-ACS-patients who are 
not anticoagulated. At present we ignore whether, in 
anticoagulated AF-patients who undergo PCI-SI and 
need TT replacing clopidogrel with either ticagrelor 
or prasugrel would be safe and more effective. As 
already mentioned, in common practice it is not rare 
to find patients who are anticoagulated (with either 
VKAs or NOACs) and who are off-label treated with 
aspirin + either ticagrelor or prasugrel.
The American College of Chest Physicians/ 
/American Heart Association (ACCF/AHA) guide-
lines on ATRs for AF-patients recommend the use 
of TT, i.e. VKAs + DAPT (aspirin + a P2Y12-antago-
nist) for thromboembolic prophylaxis [9]. The dura-
tion of TT ranges from 1 month when BMS were 
used, and to 3 months, 6 months up to 12 months 
depending on the DES-type. For anticoagulated 
patients who undergo PCI-SI, both the 2012 ACCF/ 
/AHA guidelines [9] and the 2012 ESC guidelines 
[34] gave similar recommendations: 2–4-week-
through 6-month-TT depending on the individual 
bleeding risk, type of DES, and circumstances (ACS 
or elective) of DES-implantation. In anticoagulated 
AF-patients who undergo PCI-SI, DAPT should be 
stopped after 12 months and OAC-monotherapy 
(either VKAs or NOACs) should be continued for 
long-term thromboembolic prevention.
Of note, in all guidelines these recommendations 
are only for ACS patients who underwent PCI-SI 
and not based on randomized trials. A major differ-
ence between the United States and ESC guidelines 
is the recommended international normalized ratio 
(INR) in the combination of VKAs + DAPT. The 
2012 ESC guidelines [34] recommend maintaining 
a reduced INR 2.0–2.5, whereas the 2012 ACCF/ 
/AHA guidelines [9] recommend an INR of 2.0–3.0. 
There is a great uncertainty about the best type 
and duration of the TT in AF-patients. Published 
data are in favor of limiting the duration of TT to 
the early phase and to continue with VKAs + single 
antiplatelet later on.
At the 2015 ESC congress [36] new data were 
presented on anti-thromboembolic therapy with 
antiplatelets. The BASKET-PROVE-II study [69] 
has shown that DAPT with aspirin + prasugrel 
is effective and safe in patients with stable CAD 
and that in ACS-patients it has a similar bleeding 
risk as a DAPT with aspirin + clopidogrel. The 
ATLANTIS-H24 study [cited in 36] has shown that 
it is useful to administer ticagrelor in the first 24 h 
of occurrence of ACS. In the 2015 ESC Congress, 
meta-analysis data from randomized controlled 
studies were presented and it was confirmed that 
the present knowledge is insufficient to decide about 
the optimal duration of DAPT after PCI-SI [36]. 
After PCI-SI, DAPT was significantly more effec-
tive (HR 0.78; 0.67–0.90; p = 0.001) than a 1-year 
therapy with monotherapy with aspirin in reducing 
MI, strokes and cardiovascular death, but this posi-
tive effect was accompanied by a significant increase 
for major bleeding, whereas deadly and intracranial 
bleeding complications were similar with DAPT and 
aspirin alone. However, the positive effect of DAPT 
on MACE was not statically significant in all ana-
lyzed studies. It is concluded that patients with high 
ischemic burden and low bleeding risk take advantage 
from long DAPT. Of note, these recommendations 
apply to ACS-patients who are not anticoagulated and 
should not be extrapolated to other cardiac pathologies.
In conclusion, at present we have insufficient 
information on the best ATR in AF-patients who un-
dergo PCI-SI with newer DES. In the ISAR-TRIPLE 
trial [52, 53], a 6-week TT was not inferior to 
a 6-month-TT with respect to net clinical outcomes. 
Most trials [40–49, 58, 59] also suggest that an 
ATRs with VKAs + a single P2Y12-antagonist might 
be sufficient to prevent stent-thrombosis and that 
it induces less bleeding than a VKAs + DAPT. In 
any case, under TT the INR should be maintained 
at a lower target range of 2.0–2.5 instead of 2.0–3.0 
and aspirin and clopidogrel should be given in the 
usual doses as recommended for stent implantation.
Impact of the type of coronary stents  
on thrombotic risk
After implantation the type of stent is of criti-
cal importance for the duration of the ATRs. The 
risk of stent-thrombosis is highest early after 
implantation while the risk of bleeding stays at 
similar levels after the very initial invasive phase 
[9, 40–49, 58, 59]. The time until the BMS-struts 
are covered by endothelium is considered to last 
4 weeks and consequently DAPT is required on - 
ly for this time period [9, 40–49, 58, 59]. For 
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DES-implantation modern guidelines recommend 
a 3-month DAPT in the case of implantation of an 
mTOR-inhibitor-eluting-stent, and a 6-month, 
up to 1-year DAPT in the case of implantation of 
a paclitaxel-DES [9, 40–49, 58, 59, 69–72]. The ret-
rospective ATLAS ACS 2-TIMI trial [29] compared 
the outcomes of anticoagulated patients undergoing 
PCI-SI with either BMS or DES. The incidence 
of ischemic events and all-cause mortality were 
similar, but DES-implantation was associated with 
a significantly increased risk of major bleeding in 
the follow-up period. Thus, when there is the ne-
cessity to reduce the duration of TT, BMS might 
be the preferred stent-type for patients who need 
a short duration of TT [29]. The situation is different 
in patients who were treated for stent-thrombosis 
after PCI-SI: special emphasis is on prevention of 
recurrent stent-thrombosis rather than on reduc-
ing bleeding risk and TT should be maintained for 
longer periods [9, 40–49, 58, 59, 69–72]. Recent data 
have shown that with newer DES extended duration 
of DAPT may be unnecessary and less beneficial as 
with earlier DES [9, 41–49, 58, 59, 70–73]. Indeed, 
some recent DES types have obtained clinical ap-
proval for only 3 months of DAPT [74].
At present, the duration of DAPT after PCI-SI 
with new DES is under critical discussion. It is im-
portant to solve the problems related to the best 
type and duration of ATRs in patients who need 
OAC + antiplatelets. Most groups recommend 
continuing TT for 3–6 months, depending on the 
type of DES and bleeding risk of the patient. How-
ever, it is questionable whether shorter periods 
of TT would also be effective and safer. It is still 
unproven, but it might be, that third-generation 
‘olimus’-eluting-stents require a shorter duration 
of TT. In a large clinical trial, in patients receiving 
new generation DES-zotarolimus [40, 49, 52–59], 
no differences were observed between a 3-month 
DAPT vs. a 12-month DAPT. To answer at least 
some of the missing information, the MUSICA 
interventional trial [38] is currently enrolling more 
than 2,300 patients who will be assigned to receive 
TT or DAPT: the primary endpoint is the occur-
rence of ischemia, and the secondary endpoint 
consists of bleeding complications.
Can triple therapy be individualized  
in AF-patients?
The goal should be to reduce bleeding events 
while maintaining anti-thromboembolic effective-
ness. In one study, clinical and echocardiographic 
criteria were used to decide which the best ATRs 
is for patients who undergo PCI-SI [53]. DAPT 
(aspirin + clopidogrel) was compared with TT, i.e. 
VKAs + DAPT (aspirin + clopidogrel). At 2-year 
follow-up no significant differences in terms of 
MACE were observed between DAPT or TT, sug-
gesting that this approach may be useful to balance 
risks and benefits. However, not all anticoagulated 
patients had AF and thus we ignore if these data are 
also valid for AF-patients who need TT.
In another study, anticoagulated (with VKAs) 
AF-patient who needed PCI-SI were grouped ac-
cording to their bleeding risk which was assessed 
by the HAS-BLED score [75]. More than 70% of 
patients had a score of 3 or higher. Remarkably, even 
in patients with a high bleeding risk, although bleeding 
rates were higher, the use of ATRs using VKAs were 
associated with a reduced death rate. Of note, in the 
real-world XANTUS study, the use of rivaroxaban was 
also associated with a reduced death rate [18].
Summing up, as confirmed by the data from 
the 2015 ESC congress [36], the available non-
randomized, mostly retrospective data suggest 
that TT is more effective than DAPT, or VKAs + 
+ a single antiplatelet but at the expense of increased 
bleeding rates: when compared with DAPT (aspirin + 
+ a P2Y12-antagonist) the bleeding risk is increased 
by about 2–5-fold by TT [34, 35, 52–54]. Therefore, 
as suggested from the ISAR-TRIPLE trial [52, 
53], it is wise to keep the duration of TT as short 
as possible. Unfortunately, because of their design 
and size, available studies do not provide final con-
clusions. Larger and specifically panned trials are 
needed to test the hypothesis that individualized 
therapy can optimize the net clinical data on TT.
Occlusion of the left atrial appendage
Some high-risk AF-patients would need OAC 
but cannot be given this therapy because of ex-
cessive bleeding risks or contraindicating comor-
bidities [76–78]. Thromboembolic events originate 
from the left atrium, and therefore, in selected 
high-risk AF-patients with a contraindication for 
OAC left atrial appendage closure with an occlud-
ing device can be used [76–78]. The technique is 
not without complications but is quite effective in 
reducing thromboembolic events in AF [78, 79] and 
should be considered as an alternative to OAC and 
TT in some high risk AF-patients.
General conclusions
Many AF-patients have CAD develop an ACS 
and need a PCI-SI. High-risk AF-patients need 
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OAC for prevention of thromboembolic events, 
and DAPT for prevention of stent-thrombosis. The 
unavoidable TT (OAC + DAPT) carries a strong 
potential for bleeding events, which might increase 
mortality. Based on available data some strategies 
can be recommended:
• BMS should be preferred for anticoagulated AF- 
-patients who undergo PCI-SI when there is a high 
bleeding risk or if a major surgery is expected in 
the next 6 months. After BMS-use, TT should be 
maintained for 1 month and can be followed by 
monotherapy with OAC (either NOACs, or VKAs 
with an INR 2–2.5) or a combined therapy with 
VKAs and aspirin 80–100 mg/day.
• In anticoagulated AF-patients treated with DES 
the duration of TT (VKAs + DAPT) should be kept 
as short as possible to reduce the bleeding risk. 
The newest DES should be preferred because in 
comparison to previously used DES the need for 
long-term DAPT is reduced. In AF-patients with 
low- to intermediate-bleeding risk most guidelines 
recommend a TT-duration for up to 6 months. Recent 
data from the WOEST trial [54] suggest that in these 
patients VKAs + clopidogrel 75 mg/day may suffice 
and that the addition of aspirin might be unnecessary. 
The validity of the data from WOEST trial [54] is not 
undiscussed and it might be questioned if aspirin 
should be abandoned. In this case, the duration of TT, 
i.e. VKAs + DAPT (aspirin + clopidogrel), should be 
shortened to 1 month. It should not be forgotten that 
AF-patients who receive a PCI-SI have an elevated 
bleeding risk and this argument further supports the 
notion to reduce TT to 1 month.
• After DES-implantation, when the duration of 
TT comes to the end, VKAs + clopidogrel should 
be continued for a total of 1 year. NOACs are off-
label used but are not officially recommended for 
this indication.
• During a therapy with VKAs + DAPT it is im-
portant to target INR to an INR 2.0–2.5 (lower 
than 3), especially during the combination of 
VKAs + a P2Y12-antagonist. Frequent controls are 
usually necessary to maintain the INR within this 
therapeutic range. After completion of TT, OAC 
for AF (either NOACs or VKAs, INR 2–3) can be 
continued as usual.
• It should be recalled that in the ACTIVE W study 
[39, 40] low-risk, non-anticoagulated AF-patients 
who underwent PCI-SI and were treated with 
TT had significantly more MACE when treated 
with VKAs + DAPT than with VKAs + placebo. 
Also, the occurrence of MI and major bleeding was 
signi ficantly more frequent in patients receiving 
VKAs + clopidogrel than in those receiving VKAs + 
+ placebo. Thus, in low-risk AF-patients who undergo 
PCI-SI, ATRs with either TT or VKAs + clopidogrel 
reduce the risk of major vascular events, especially 
stroke, but increase the risk of major hemorrhage.
• In AF-patients who need a TT, at present third-
generation P2Y12 antagonists are not recommended 
because the bleeding risk may be unforeseeably 
high. Nonetheless, clinical experience shows 
that some patients are off-label treated with this 
combination against the recommended guidelines. 
Further trials are needed for ATRs with the third-
generation P2Y12 antagonists.
• The use of NOACs instead of VKAs for TT is 
currently not recommended. If, nonetheless, the 
physician decides to use NOACs for TT, rivaroxa-
ban in a very low dose (2.5-mg bid) may be con-
sidered. The PIONEER trial [28] will test if this 
TT is effective and safe in AF-patients. However, 
currently only an extrapolation from scarce existing 
data is available to support the use of NOACS for 
TT in AF-patients.
• With TT (VKAs + DAPT) and also with VKAs + 
+ a single antiplatelet patients should be treated 
with a proton pump inhibitor to reduce the risk 
of gastrointestinal bleeding. Obviously, drugs 
increasing the risk, such as non-steroidal anti-
inflammatory drugs should be avoided.
• In high-risk AF patients with a high risk for 
bleeding occlusion of the left atrial appendage 
might be a valuable option to avoid OAC.
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